An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells.

Yoshida, Misa; Oda, Chihiro; Mishima, Keishiro; Tsuji, Itsuki; Obika, Satoshi; Shimojo, Masahito

Yoshida, Misa; Oda, Chihiro; Mishima, Keishiro; Tsuji, Itsuki; Obika, Satoshi; Shimojo, Masahito.

Afiliación

Yoshida M; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Oda C; School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Mishima K; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Tsuji I; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Obika S; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Shimojo M; School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Cancer Cell Int ; 23(1): 8, 2023 Jan 17.

Article en En | MEDLINE | ID: mdl-36650528

Palabras clave

Antisense oligonucleotide; Gapmer; Prostate cancer; REST/NRSF; SCLC; SRRM4; Small cell lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancer Cell Int Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google